Another mid-late stage Alzheimer’s flop, this time for Lilly

13th February 2020 Uncategorised 0

Earlier this month, Roche also announced a gantenerumab Alzheimer’s failure, and last year, Biogen and Eisai stopped two global Phase III trials of aducanumab.

More: Another mid-late stage Alzheimer’s flop, this time for Lilly
Source: News